Literature DB >> 11418349

Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV.

M Arens1.   

Abstract

The term 'genotyping' describes the genetic characterization of a genome. The genotype analysis is performed to identify mutations that differentiate one individual or strain from another. The mutations may confer resistance to specific antiviral drugs or they may simply allow classification of a strain as to 'type' and 'subtype'. There are four human viruses for which genotype information is clinically useful. Hepatitis B virus (HBV) infections are being treated with antiretroviral drugs and resistance after prolonged treatment is common. Since HBV cannot be cultured, the only method of detecting resistance-conferring mutations in the genome is a genotypic analysis. Hepatitis C virus (HCV) infection can be cured by treatment with the combination of interferon and ribavirin but certain strains of virus are more resistant to treatment than others. The current recommendations are that all HCV type 1 infections be treated for 12 months whereas other types may be successfully treated in 6 months. Since interferon treatment may have significant side effects, the determination of HCV genotype is an important aspect of this therapeutic regimen. Treatment of cytomegalovirus (CMV) disease with nucleoside analogues occasionally results in resistant virus with mutations in the phosphotransferase gene (UL97) and/or the DNA polymerase gene (UL54) that can be tested with phenotypic or genotypic assays. Since CMV grows very slowly, it may be more clinically useful to perform a rapid genotypic assay although only the UL97 gene can be efficiently genotyped. Finally, the virus for which genotyping has become the standard of care, human immunodeficiency virus type 1 (HIV-1) can now be genotyped routinely by many clinical virology labs experienced with molecular amplification methods and automated DNA sequencing technology. All currently-available antiretroviral drugs are directed against either the protease or reverse transcriptase genes of HIV-1 and the mutations within these genes that confer resistance have been well described. Sequence-based genotyping methods are not necessarily the best approach for routine genotyping of these four viruses, but sequencing is the gold standard from which other methods are developed and against which they are compared.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418349     DOI: 10.1016/s1386-6532(01)00156-1

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  12 in total

1.  Genetic diversity within human erythroviruses: identification of three genotypes.

Authors:  Annabelle Servant; Syria Laperche; Francis Lallemand; Valérie Marinho; Guillemette De Saint Maur; Jean François Meritet; Antoine Garbarg-Chenon
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

2.  Novel method for probing the specificity binding profile of ligands: applications to HIV protease.

Authors:  Woody Sherman; Bruce Tidor
Journal:  Chem Biol Drug Des       Date:  2008-03-31       Impact factor: 2.817

3.  Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma.

Authors:  Hart B Moss; Sai Chavala; Emil Say; Melissa B Miller
Journal:  J Clin Microbiol       Date:  2012-02-15       Impact factor: 5.948

Review 4.  Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis.

Authors:  Seyed-Moayed Alavian; Bita Behnava; Seyed Vahid Tabatabaei
Journal:  Eur J Clin Pharmacol       Date:  2010-09-21       Impact factor: 2.953

5.  Evaluation of the editing process in human immunodeficiency virus type 1 genotyping.

Authors:  Diana D Huang; Susan H Eshleman; Donald J Brambilla; Paul E Palumbo; James W Bremer
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

6.  Hepatitis C virus (HCV) genotyping by annealing reverse transcription-PCR products with genotype-specific capture probes.

Authors:  Jungmin Rho; Jong Soon Ryu; Wonhee Hur; Chang Wook Kim; Jeong Won Jang; Si Hyun Bae; Jong Young Choi; Sung Key Jang; Seung Kew Yoon
Journal:  J Microbiol       Date:  2008-02       Impact factor: 3.422

7.  Identification of HCV genotypes in HCV infected blood donors.

Authors:  Zohreh Sharifi; Mahmood Mahmoodian Shooshtari; Fahimeh Rangbar Kermani
Journal:  Indian J Microbiol       Date:  2010-10-30       Impact factor: 2.461

8.  Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis.

Authors:  Seyed Moayed Alavian; Seyed Vahid Tabatabaei; Bita Behnava; Nastaran Mahboobi
Journal:  Hepat Mon       Date:  2011-08       Impact factor: 0.660

9.  Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.

Authors:  Andrea Hauser; Claudia Kuecherer; Andrea Kunz; Piotr Wojtek Dabrowski; Aleksandar Radonić; Andreas Nitsche; Stefanie Theuring; Norbert Bannert; Julius Sewangi; Paulina Mbezi; Festo Dugange; Gundel Harms; Karolin Meixenberger
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 10.  Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

Authors:  Martin Stürmer; Hans Wilhelm Doerr; Lutz Gürtler
Journal:  Med Microbiol Immunol       Date:  2009-06-04       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.